Industry News (Acquisitions)

Licensed Peptide Treatment Regulates Abnormal Immune Responses in HIV Patients

Published in AIDS Weekly, June 1st, 1998

Allergene, San Mateo, California, announced that it has acquired rights to a T-cell receptor peptide that can reverse some of the immune system abnormalities seen with HIV infection and other diseases of the immune system.

The peptide, dubbed ALG889, was developed and tested in animal studies by a team of scientists led by Dr. Jack Marchalonis and Dr. Ronald W. Watson, University of Arizona.

Commenting on the results of the animal studies, Marchalonis said, "When this peptide was administered to mice with an AIDS like viral infection (the MAIDS model), it reversed the immunologic abnormality, and prevented opportunistic infections. Human studies...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1998-06-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry